Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy
Article first published online: 11 JAN 2012
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology
Clinical & Experimental Immunology
Volume 167, Issue 2, pages 206–215, February 2012
How to Cite
Durrant, L. G., Noble, P. and Spendlove, I. (2012), Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clinical & Experimental Immunology, 167: 206–215. doi: 10.1111/j.1365-2249.2011.04516.x
- Issue published online: 11 JAN 2012
- Article first published online: 11 JAN 2012
- Accepted manuscript online: 31 OCT 2011 10:32AM EST
- Accepted for publication 24 October 2011
- cancer vaccine;
- monoclonal antibody
OTHER THEMES PUBLISHED IN THIS IMMUNOLOGY IN THE CLINIC REVIEW SERIES
Metabolic Diseases, Host Responses, Allergies, Autoinflammatory Diseases, Type 1 diabetes and viruses.
Research into aberrant glycosylation and over-expression of glycolipids on the surface of the majority of cancers, coupled with a knowledge of glycolipids as functional molecules involved in a number of cellular physiological pathways, has provided a novel area of targets for cancer immunotherapy. This has resulted in the development of a number of vaccines and monoclonal antibodies that are showing promising results in recent clinical trials.